Home › News › Quality / GMP

Sanofi Receives EC Approval for VaxRabeo Rabies Vaccine Across All Age Groups

Sanofi Receives EC Approval for VaxRabeo Rabies Vaccine Across All Age Groups

Sanofi has received European Commission approval for VaxRabeo (rabies virus inactivated strain Wistar) for pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) against rabies across all age groups. The approval marks the vaccine’s first marketing authorisation and follows a positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026.

VaxRabeo is manufactured using Vero-cell technology and is designed to offer improved thermostability and a longer shelf life than Sanofi’s existing rabies vaccines. The vaccine has a shelf life of 60 months and can maintain stability at temperatures of up to 27°C for 96 hours before reconstitution. It is also formulated to minimise the risk of allergic reactions.

The European Commission’s approval is supported by a clinical programme comparing VaxRabeo with Sanofi’s existing standard-of-care rabies vaccines, Verorab and Imovax Rabies, in both PrEP and PEP settings. The studies covered all age groups and World Health Organization (WHO)-recommended vaccination schedules.

In PrEP studies, two-dose and three-dose regimens of VaxRabeo achieved protective antibody levels comparable to those observed with Verorab and Imovax Rabies in adults and children. Booster doses administered 12 or 24–36 months after the last PrEP dose demonstrated high boostability. In PEP studies, VaxRabeo showed a similar immunogenicity profile to the existing Sanofi vaccines, whether administered with or without rabies immunoglobulins. All participants receiving the vaccine intramuscularly achieved protective antibody levels. Across the clinical programme, VaxRabeo demonstrated a safety profile consistent with existing rabies vaccines, with no significant safety concerns identified.

The vaccine supports flexible vaccination schedules, including the WHO-recommended two-dose PrEP regimen and a four-dose PEP regimen for individuals who have not previously been vaccinated. PEP can be administered with or without rabies immunoglobulin, depending on the clinical requirement.

Rabies is a viral zoonotic disease that affects the central nervous system and is present in approximately 150 countries. According to WHO estimates, the disease causes around 59,000 deaths globally each year. Transmission occurs primarily through the saliva of infected animals, most commonly through dog bites, scratches or contact with broken skin. Other mammals, including cats, bats, foxes, raccoons, skunks, jackals and mongooses, can also transmit the virus.

Although rabies is vaccine preventable, it remains a significant public health concern, particularly in Asia and Africa. Once clinical symptoms appear, the disease is almost always fatal. Around 29 million people receive post-exposure vaccination each year, according to the WHO. Children account for a disproportionate share of exposure, with approximately 40 percent of people bitten by suspected rabid animals being under 15 years of age.

Commenting on the approval, Thomas Triomphe, Head of Vaccines at Sanofi, said that timely vaccination can prevent rabies deaths and described the authorisation as a milestone for the company, reflecting its five decades of experience in rabies protection and vaccine development.

VaxRabeo uses the same viral strain as Sanofi’s Verorab and Imovax Rabies vaccines, which have been used for more than five decades. The approval expands Sanofi’s rabies vaccine portfolio with a formulation offering a five-year shelf life and improved temperature stability.

More news about: quality / gmp | Published by News Bureau | November - 20 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members